{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Kymera Therapeutics, Inc.
Kymera Therapeutics Hits New 52-Week High of $63.29, Up 83.57%
Kymera Therapeutics, Inc. has achieved a new 52-week high of USD 63.29, reflecting an 83.57% increase over the past year. With a market capitalization of approximately USD 3,093 million, the company operates at a loss and has a unique financial structure, indicated by its negative price-to-earnings ratio.
Kymera Therapeutics Hits New 52-Week High at $60.00, Up 74.81% Year-to-Date
Kymera Therapeutics, Inc. achieved a new 52-week high of USD 60.00 on October 13, 2025, reflecting a significant increase from its low of USD 19.45. With a market capitalization of USD 3,093 million, the company operates in the competitive Pharmaceuticals & Biotechnology sector, despite currently reporting losses.
Kymera Therapeutics Hits New 52-Week High of $59.00, Up 69%
Kymera Therapeutics, Inc. has achieved a new 52-week high of USD 59.00, significantly up from its low of USD 19.45. The company, with a market cap of approximately USD 3,093 million, has shown strong stock performance despite ongoing losses and a negative return on equity.
Kymera Therapeutics Hits New 52-Week High of $58.93, Up 65.21%
Kymera Therapeutics, Inc. achieved a new 52-week high of USD 58.93 on September 30, 2025, reflecting a significant performance increase from its 52-week low. The company, with a market cap of approximately USD 3,093 million, continues to attract attention despite its loss-making status and challenging financial metrics.
Kymera Therapeutics Hits New 52-Week High of $56.81, Up 64% Year-to-Date
Kymera Therapeutics, Inc. achieved a new 52-week high, reflecting strong performance in the pharmaceuticals and biotechnology sector. With a market capitalization of USD 3,093 million, the company has seen significant growth over the past year, despite being loss-making and lacking a dividend yield. Key financial metrics indicate a unique financial structure.
Kymera Therapeutics Hits New 52-Week High of $53.84, Reflecting Strong Growth
Kymera Therapeutics, Inc. achieved a new 52-week high of USD 53.84 on September 25, 2025, highlighting its strong performance in the Pharmaceuticals & Biotechnology sector. The company has seen a significant increase over the past year, attracting attention despite being loss-making, with key financial metrics indicating its market valuation and positioning.
Kymera Therapeutics Experiences Revision in Stock Evaluation Amid Mixed Market Signals
Kymera Therapeutics, Inc. has recently revised its evaluation amid market fluctuations, with its stock price at $49.13. The company has shown significant volatility over the past year, achieving notable returns compared to the S&P 500, indicating resilience in a competitive landscape despite mixed technical signals.
Is Kymera Therapeutics, Inc. technically bullish or bearish?
As of August 5, 2025, Kymera Therapeutics, Inc. has a mildly bullish technical trend, supported by positive MACD and Bollinger Bands indicators, daily moving averages, and strong performance relative to the S&P 500.
Is Kymera Therapeutics, Inc. technically bullish or bearish?
As of June 17, 2025, the market trend is mildly bullish, supported by the weekly MACD and Bollinger Bands, despite some caution from the monthly indicators and mixed signals from daily moving averages.
What does Kymera Therapeutics, Inc. do?
Kymera Therapeutics, Inc. is a small-cap biotechnology company focused on pharmaceuticals, reporting net sales of $22 million and a net loss of $66 million as of March 2025. The company has a market cap of approximately $3.02 billion and does not currently pay dividends.
How big is Kymera Therapeutics, Inc.?
As of Jun 18, Kymera Therapeutics, Inc. has a market capitalization of $3.02 billion, with net sales of $58.88 million and a net profit of -$240.88 million over the last four quarters. The company reported shareholder's funds of $835.62 million and total assets of $978.03 million as of Dec 24.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
